secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-029165
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics reports FY2024 net loss $69M, cash $1.03B, positive JANX007 data
--------------------------------------------------------------------------------

- Cash and short-term investments $1.03B at year-end 2024, up from $344M in 2023, largely from $402.5M December offering.
- Net loss $69.0M for FY2024 ($20.2M Q4), vs $58.3M prior year; R&D spend $68.4M.
- JANX007 PSMA-TRACTr Phase 1: 100% PSA50, 63% PSA90, 50% ORR (4/8), well-tolerated safety; data cutoff Nov 15, 2024.
- JANX008 EGFR TRACTr Phase 1 enrollment ongoing; data update and R&D Day planned for 2025.
- Zachariah McIver promoted to Chief Medical Officer; he previously served as Amgen's Executive Medical Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017025029165/0000950170-25-029165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017025029165/janx-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-029165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer